|
|
▲Celltrion Corona 19 antibody treatment “Rekironaju” (ingredient name Legdanvimab CT-P59). Yonhap News |
[에너지경제신문 김세찬 기자] At the time of a recent cyber attack on the European Medicines Agency (EMA), it was revealed that there was illegal access to documents related to Celltrion’s Corona 19 antibody treatment drug’Recyronazu’ (ingredient name Legdanvimab CT-P59).
However, it is said that there is no leakage or damage caused by this.
Celltrion announced on the 22nd that it had been notified of this from EMA through an announcement on the company’s website.
Celltrion is currently negotiating with EMA to apply for an item permit in Rekirona. For this reason, some documents related to the state of Rekirona have been submitted to EMA.
Celltrion said, “Not only us, but also some multinational corporations such as US Moder and German Bioentech are known to have suffered the same type of damage,” said Celltrion. “We believe that this cyber attack did not occur specifically for us.” .
He emphasized that the patient’s personal information related to medicine was not leaked.
Celltrion said, “It is possible that some of the documents submitted to EMA were leaked to the outside due to this incident,” and “the document does not contain any personal information of the patient.”
Celltrion is also continuously monitoring its own IT system, and has confirmed that it has not seen any leakage or damage to date.
Prior to this, EMA announced that a cyber attack occurred on the 9th of last month (local time) and that an investigative agency is investigating it. On the 12th of this month, it was revealed that some data related to Corona 19 drugs and vaccines, which were illegally accessed during a cyber attack, were leaked on the Internet.
On the other hand, Celltrion antibody treatment’Rekironaju’ was recommended by the Ministry of Food and Drug Safety’s Covid-19 treatment verification advisory group to approve the item on the premise of conducting phase 3 clinical trials.